A Systematic Review of the State of Economic Evaluation for Health Care in India

Applied Health Economics and Health Policy

Volumn 13, Issue 6, 2015, Pages 595-613

  Prinja, Shankar ^a   Chauhan, Akashdeep Singh ^a   Angell, Blake ^b   Gupta, Indrani ^c   Jan, Stephen ^b,d  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c UNIVERSITY OF DELHI   (India)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COMMUNICABLE DISEASE; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FUNDING; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INDIA; INVESTMENT; MANAGEMENT; PUBLIC HEALTH; REVIEW; SYSTEMATIC REVIEW; COST BENEFIT ANALYSIS; DELIVERY ROOM; ECONOMICS;

COST-BENEFIT ANALYSIS; DELIVERY ROOMS; INDIA;

EID: 84948585911     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-015-0201-6     Document Type: Review

References (148)

1. Husereau D, Culyer AJ, Neumann P, Jacobs P. How do economic evaluations inform health policy decisions for treatment and prevention in Canada and the United States? Appl Health Econ Health Policy. 2015;13(3):273–9. Available from: http://link.springer.com/10.1007/s40258-014-0133-6.
2. Ontario Ministry of Health and Long Term Care. Ontario guidelines for economic analysis of pharmaceutical products. 1994.
3. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics. 2006;24(11):1133–42.
4. Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health. 2009;12(Suppl 3):S4–11.
5. Thatte U, Hussain S, de Rosas-Valera M, Malik MA. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan. Value Health. 2009;12(Suppl 3S):18–25.
6. Ministry of Health and Family Welfare. Government of India. New Delhi: National Vacine Policy; 2011.
7. Department of Health Research. XII Plan document (2012-2017). New Delhi: Ministry of Health and Famuliy Welfare, Governemnt of India; 2012.
8. Indian chapter of International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Internet]. Available from: http://www.isporindia.com/. Cited 14 Mar 2015.
9. Desai PR, Chandwani HS, Rascati KL. Assessing the quality of pharmacoeconomic studies in India: a systematic review. Pharmacoeconomics. 2012;30(9):749–62.
10. Mishra D, Nair S. Systematic literature review to evaluate and characterize the health economics and outcomes research studies in India. Perspect Clin Res. 2015;6(1):20–33.
11. Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library; 2008.
12. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313(7052):275–83. Available from: http://www.bmj.com/content/313/7052/275.
13. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. 2004;8(36):iii–iv (ix–xi, 1–158).
14. La Torre G, Nicolotti N, De Waure C, Ricciardi W. Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine. J Public Health (Bangkok). 2011;19:103–11.
15. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease control priorities in developing countries. Washington (DC):World Bank Publications; 2006.
16. Lok Sabha Secretariat. Reference note No. 6/RN/Ref./2013: price rise/inflation. Parliament Library and Reference, Research, Documentation and Information Service (lAARDIS). 2013.
17. Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al. Making choices in health: WHO guide to cost-effectiveness analysis: World Health Organization; 2003.
18. The World Bank. [Internet]. Available from: http://data.worldbank.org/country/india. Cited 7 Mar 2015.
19. Aggarwal K, Khandpur S, Khanna N, Sharma VK, Pandav CS. Comparison of clinical and cost-effectiveness of psoralen? ultraviolet A versus psoralen? sunlight in the treatment of chronic plaque psoriasis in a developing economy. Int J Dermatol. 2013;52(4):478–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23431966.
20. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost effectiveness of universal hepatitis B immunization in a low income country with intermediate endimicity using a Markov model. J Hepatol. 2003;38(2):215–22.
21. Aggarwal R, Ghoshal UC, Naik SR. Treatment of Chronic hepatitis B with interferon-alpha: Cost-effectiveness in developing countries. Natl Med J India. 2002;15(6):320–7.
22. Alexander A, John KR, Jayaraman T, Oommen A, Venkata Raghava M, Dorny P, et al. Economic implications of three strategies for the control of taeniasis. Trop Med Int Health. 2011;16(11):1410–6.
23. Awasthi S, Pande VK, Fletcher RH. Effectiveness and cost-effectiveness of albendazole in improving nutritional status of pre-school children in urban slums. Indian Pediatr. 2000;37(1):19–29.
24. Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol. 2009;41(1):9–14.
25. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis. 2010;50(3):416–25.
26. Bhagia LJ, Sadhu HG. Cost-benefit analysis of installing dust control devices in the agate industry, Khambhat (Gujarat). Indian J Occup Environ Med. 2008;12(3):128–31.
27. Bhatia MR, Fox-Rushby J, Mills A. Cost-effectiveness of malaria control interventions when malaria mortality is low: Insecticide-treated nets versus in-house residual spraying in India. Soc Sci Med. 2004;59(3):525–39.
28. Bhatia SJ, Kulkarni SG. Cost-effectiveness of Helicobacter pylori eradication in India: to live and let live … expensively? Indian J Gastroenterol. 1997;16(Suppl 1):S25–8.
29. Brown HS, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in India. Health Promot Int. 2013;28(2):178–86.
30. Buttorff C, Hock RS, Weiss HA, Naik S, Araya R, Kirkwood BR, et al. Economic evaluation of a task-shifting intervention for common mental disorders in India. Bull World Health Organ. 2012;90(11):813–21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3506405&tool=pmcentrez&rendertype=abstract.
31. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775–84 (Elsevier Ltd).
32. Chow J, Klein EY, Laxminarayan R. Cost-effectiveness of “golden mustard” for treating vitamin a deficiency in India. PLoS One. 2010;5(8):e12046.
33. Clark AD, Griffiths UK, Abbas SS, Rao KD, Privor-Dumm L, Hajjeh R, et al. Impact and cost-effectiveness of haemophilus influenzae type b conjugate vaccination in india. J Pediatr [Internet]. 2013;163(1):S60–72. doi:10.1016/j.jpeds.2013.03.032(Elsevier Ltd).
34. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008;26(50):6305–16.
35. Dabral M. Cost-effectiveness of supplementary immunization for measles in India. Indian Pediatr. 2009;46(3):957–62.
36. Dandona L, Kumar SGP, Kumar GA, Dandona R. Cost-effectiveness of HIV prevention interventions in Andhra Pradesh state of India. BMC Health Serv Res. 2010;10:117.
37. Dhivya PS, Swathy G, Pal S. Pharmacoeconomics of antihypertensive drugs prescribed in a multispecialty hospital in South India. Asian J Pharm. 2014;8(3):178–82.
38. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, et al. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.
39. Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health. 2011;8(5):1271–86.
40. Dowdy DW, Steingart KR, Pai M. Serological testing versus other strategies for diagnosis of active tuberculosis in india: a cost-effectiveness analysis. PLoS Med. 2011;8(8):e1001074.
41. Dranitsaris G, Truter I, Lubbe MS, Sriramanakoppa NN, Mendonca VM, Mahagaonkar SB. Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. Int J Technol Assess Health Care. 2011;27(1):23–30.
42. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: A combined analysis of 12 mathematical models. Lancet Glob Heal. 2014;2(1):e23–34.
43. Esposito DH, Tate JE, Kang G, Parashar UD. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis. 2011;52(2):171–7.
44. Ferroussier O, Kumar MKA, Dewan PK, Nair PKJ, Sahu S, Wares DF, et al. Cost and cost-effectiveness of a public-private mix project in Kannur District Kerala, India, 2001–2002. Int J Tuberc Lung Dis. 2007;11(7):755–61.
45. Floyd K, Arora VK, Murthy KJR, Lonnroth K, Singla N, Akbar Y, et al. Cost and cost-effectiveness of PPM-DOTS for tuberculosis control: evidence from India. Bull World Health Organ. 2006;84(05):437–45.
46. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, et al. Clinical impact and cost effectivceness of antiretroviral therapy in India: starting criteria and second line therapy. AIDS. 2007;21(Suppl 4):S117–28.
47. Frick KD, Riva-Clement L, Shankar MB. Screening for refractive error and fitting with spectacles in rural and urban India: cost-effectiveness. Ophthalmic Epidemiol. 2009;16(6):378–87.
48. Fung IC-H, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7:195.
49. Ghoshal UC, Aggarwal R, Baba CS. Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management strategies. Expert Opin Pharmacother. 2003;4:1593–603.
50. Gogtay NJ, Kadam VS, Desai S, Kamtekar KD, Dalvi SS, Kshirsagar NA. A cost-effectiveness analysis of three antimalarial treatments for acute, uncomplicated Plasmodium falciparum malaria in Mumbai. India. J Assoc Physicians India. 2003;51:877–9.
51. Goldie SJ, O’Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 2008;26(32):4080–93.
52. Goldie SJ, Sweet S, Carvalho N, Natchu UCM, Hu D. Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. PLoS Med. 2010;7(4):e1000264.
53. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353(20):2158–68.
54. Goodchild M, Sahu S, Wares F, Dewan P, Shukla RS, Chauhan LS, et al. A cost-benefit analysis of scaling up tuberculosis control in India. Int J Tuberc Lung Dis. 2011;15(3):358–62.
55. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the crash-2 trial. PLoS One. 2011;6(5):e18987.
56. Gupta M, Prinja S, Kumar R, Kaur M. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan. 2013;28(1):51–61.
57. Jeuland M, Cook J, Poulos C, Clemens J, Whittington D. Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009;12(6):899–908.
58. Jothi R, Ismail AM, Senthamarai R, Pal S. A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients. Indian J Pharmacol. 2010;42(6):362–5.
59. Kochhar P, Suvarna V, Duttagupta S, Sarkar S. Cost-effectiveness study comparing cefoperazone-sulbactam to a three-drug combination for treating intraabdominal infections in an Indian health-care setting. Value Health. 2008;11(Suppl 1):S33–8.
60. Krishnamoorthy K, Rajendran R, Sunish IP, Reuben R. Cost effectiveness of the use of vectrol control and mass drug administration, seperately or in combination, against lymphatic filariasis. Ann Trop Med Parasitol. 2002;96:S77–90.
61. Kumar M, Birch S, Maturana A, Gafni A. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India. Health Policy (N Y). 2006;77(2):233–43.
62. Lee BY, Bacon KM, Shah M, Kitchen SB, Connor DL, Slayton RB. The economic value of a visceral leishmaniasis vaccine in Bihar State, India. Am J Trop Med Hyg. 2012;86(3):417–25.
63. Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynecol Obstet [Internet]. 2011;115 Suppl:S20–5. doi:10.1016/S0020-7292(11)60007-6(International Federation of Gynecology and Obstetrics).
64. Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Heal. 2009;14(3):332–7.
65. Mahajan R, Gupta A, Gupta RS, Gupta K. Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: a comparative study. J Pharmacol Pharmacother. 2010;1(2):82–6.
66. Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel. J Matern Fetal Neonatal Med. 2013;26(8):802–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23311860.
67. Massad E, Behrens BC, Coutinho F a B, Behrens RH. Cost risk benefit analysis to support chemoprophylaxis policy for travellers to malaria endemic countries. Malar J [Internet]. 2011;10(1):130. Available from: http://www.malariajournal.com/content/10/1/130(BioMed Central Ltd).
68. McNeil BJ, Dudley RA, Hoop B, Metz C, Thompson M, Adelstein SJ. A cost-effectiveness analysis of screening for hepatitis B surface antigen in India. Med Decis Making. 1981;1(4):345–59.
69. McNeil BJ, Thompson M, Adelstein SJ. Cost effectiveness calculations for the diagnosis and treatment of tuberculous meningitis. Eur J Nucl Med. 1980;5(3):271–6.
70. Meheus F, Balasegaram M, Olliaro P, Sundar S, Rijal S, Faiz MA, et al. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis. 2010;4(9). doi:10.1371/journal.pntd.0000818.
71. Miller MA, Kane M. Routine hepatitis B immunisation in India: cost-effectiveness assessment. Indian J Pediatr. 2000;67(4):299–300.
72. Mukherjee K. Cost-effectiveness of childbirth strategies for prevention of mother-to-child transmission of HIV among mothers receiving nevirapine in India. Indian J Community Med. 2010;35(1):29–33.
73. Okonkwo QL, Draisma G, Der Kinderen A, Brown ML, De Koning HJ. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst. 2008;100(18):1290–300.
74. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis. 2006;33(10):S145–52.
75. Pandav C. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public Health. 2012;56(1):37.
76. Patel AB, Dhande LA, Rawat MS. Economic evaluation of zinc and copper use in treating acute diarrhea in children: a randomized controlled trial. Cost Eff Resour Alloc. 2003;1(1):7.
77. Patel V, Chisholm D, Rabe-Hesketh S, Dias-Saxena F, Andrew G, Mann A. Efficacy and cost-effectiveness of drug and psychological treatments for common mental disorders in general health care in Goa, India: A randomised, controlled trial. Lancet. 2003;361(9351):33–9.
78. Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, et al. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. Hepatol Int. 2008;2(2):231–6.
79. Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, et al. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7(4):e36001.
80. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programs in an Indian urban slum community. J Health Popul Nutr. 2004;22(3):311–21.
81. Prinja S, Bahuguna P, Rudra S, Gupta I, Kaur M, Mehendale SM, et al. Cost effectiveness of targeted HIV prevention interventions for female sex workers in India. Sex Transm Infect. 2011;87(4):354–61.
82. Rachapelle S, Legood R, Alavi Y, Lindfield R, Sharma T, Kuper H, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in india. Ophthalmology [Internet]. 2013;120(3):566–73. doi:10.1016/j.ophtha.2012.09.002(Elsevier Inc.).
83. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions. Diabetes Care. 2007;30(10):2548–52.
84. Reid S. Estimating the burden of disease from unsafe injections in India: a cost-benefit assessment of the auto-disable syringe in a country with low blood-borne virus prevalence. Indian J Community Med. 2012;37(2):89–94.
85. Rheingans R, Anderson JD, Anderson B, Chakraborty P, Atherly D, Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. Vaccine [Internet]. 2014;32 Suppl 1:A140–50. doi:10.1016/j.vaccine.2014.05.073(Elsevier Ltd).
86. Rob B, Vinod JA, Monica P, Balraj A, Job A, Norman G, et al. Costs and health effects of screening and delivery of hearing aids in Tamil Nadu, India: an observational study. BMC Public Health. 2009;9:135.
87. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ. 2009;339:b3653.
88. Sahni M, Jindal K, Abraham M, Aruldas K, Puliyel JM. Hepatitis B Immunization: cost calculation in a community based study in India. Indian J Gastroenterol. 2004;23(1):16–8.
89. Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: a cost-effectiveness analysis. BMC Cardiovasc Disord. 2010;10:13.
90. Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins - Enoxaparin, nadroparin and dalteparin: the ESCAPe-END study. Pharmacology. 2006;78(3):136–43.
91. Singh AJ, Garner P, Floyd K. Cost-effectiveness of public-funded options for cataract surgery in Mysore, India. Lancet. 2000;355(9199):180–4.
92. Singh K. Economic evaluation of Japanese encephalitis vaccination programme in Uttar Pradesh, India: a cost-benefit study. J Vector Borne Dis. 2014;51(1):47–52.
93. Sood S, Nambiar D. Comparative cost-effectiveness of the components of a behavior change communication campaign on HIV/AIDS in North India. J Health Commun. 2006;11(Suppl 2):143–62.
94. Sriram S, Aiswaria V, Cijo A, Mohankumar T. Antibiotic sensitivity pattern and cost-effectiveness analysis of antibiotic therapy in an Indian tertiary care teaching hospital. J Res Pharm Pract. 2013;2(2):70. Available from: http://www.jrpp.net/text.asp?2013/2/2/70/117386.
95. Srivastava A, Srinivas G, Misra MC, Pandav CS, Seenu V, Goyal A. Cost-effectiveness analysis of laparoscopic versus minilaparotomy cholecystectomy for gallstone disease. A randomized trial. Int J Technol Assess Health Care. 2001;17(4):497–502.
96. Subramaniam B, Madan R, Sadhasivam S, Sennaraj B, Tamilselvan P, Rajeshwari S, et al. Dexamethasone is a cost-effective alternative to ondansertron in preventing PONV after paediatric strabismur repair. Br J Anaesth. 2001;86(1):84–9.
97. Subramanian S, Sankaranarayanan R, Bapat B, Somanathan T, Thomas G, Mathew B, et al. Cost-effectiveness of oral cancer screening: Results from a cluster randomized controlled trial in India. Bull World Health Organ. 2009;87(3):200–6.
98. Suraratdecha C, Ramana CV, Kaipilyawar S, Krishnamurthy J, Sivalenka S, Ambatipudi N, et al. Cost and effectiveness analysis of immunization service delivery support in Andhra Pradesh, India. Bull World Health Organ. 2008;86(3):221–8.
99. Sutherland T, Bishai DM. Cost-effectiveness of misoprostol and prenatal iron supplementation as maternal mortality interventions in home births in rural India. Int J Gynecol Obstet [Internet]. 2009;104(3):189–93. doi:10.1016/j.ijgo.2008.10.011(Elsevier Ireland Ltd).
100. Sutherland T, Meyer C, Bishai DM, Geller S, Miller S. Community-based distribution of misoprostol for treatment or prevention of postpartum hemorrhage: Cost-effectiveness, mortality, and morbidity reduction analysis. Int J Gynecol Obstet [Internet]. 2010;108(3):289–94. doi:10.1016/j.ijgo.2009.11.007(International Federation of Gynecology and Obstetrics).
101. Thaker S, Mehta D, Shah H, Dave J, Kikani K. A comparative study to evaluate efficacy, safety and cost-effectiveness between Whitfield′s ointment + oral fluconazole versus topical 1 % butenafine in tinea infections of skin. Indian J Pharmacol. 2013;45(6):622. Available from: http://www.ijp-online.com/text.asp?2013/45/6/622/121378.
102. Thaker S, Mehta D, Shah H, Dave J, Mundhava S. A comparative randomized open label study to evaluate efficacy, safety and cost effectiveness between topical 2 % sertaconazole and topical 1 % butenafine in tinea infections of skin. Indian J Dermatol. 2013;58(6):451. Available from: http://www.e-ijd.org/text.asp?2013/58/6/451/119955.
103. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled β-agonists v. oral salbutamol in asthma: A randomized double-blind cross-over study. Natl Med J India. 1996;9(4):159–62.
104. Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS One. 2010;5(9):1–9.
105. Van’t Hoog AH, Cobelens F, Vassall A, Van Kampen S, Dorman SE, Alland D, et al. Optimal triage test characteristics to improve the cost-effectiveness of the Xpert MTB/RIF assay for TB diagnosis: A decision analysis. PLoS One. 2013;8(12):e82786.
106. Vassall A, Pickles M, Chandrashekar S, Boily M-C, Shetty G, Guinness L, et al. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India. Lancet Glob Heal [Internet]. 2014;2(9):e531–40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2214109X14702773(Vassall et al. Open Access article distributed under the terms of CC BY-NC-ND).
107. Venkatesh KK, Becker JE, Kumarasamy N, Nakamura YM, Mayer KH, Losina E, et al. Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India. PLoS One. 2013;8(5):e64604.
108. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: An extended cost-effectiveness analysis. Vaccine [Internet]. 2013;31(42):4902–10. doi:10.1016/j.vaccine.2013.07.014(Elsevier Ltd).
109. Vijendra R, Kumar A, Girish K, Harsha R, Reddy V, Lakshmi P. Cost-effectiveness analysis of baclofen and chlordiazepoxide in uncomplicated alcohol-withdrawal syndrome. Indian J Pharmacol. 2014;46(4):372. Available from: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2014;volume=46;issue=4;spage=372;epage=377;aulast=Reddy.
110. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369:1715–25. Available from: http://www.nejm.org/doi/full/10.1056/NEJMsa1214720.
111. Ghoshal UC, Aggarwal R, Kumar S, Naik SR. Pneumatic dilation versus intrasphincteric botulinum toxin injection in the treatment of achalasia cardia in India: an economic analysis. Indian J Gastroenterol. 2002;21(5):193–6.
112. Prakash C. Crucial factors that influence cost effectiveness of Universal Hepatitis B immunization in India. Int J Technol Assess Health Care. 2003;19(1):28–40.
113. Pantoja A, Lönnroth K, Lal SS, Chauhan LS. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness. Int J Tuberc Lung Dis. 2009;13(6):705–12.
114. Bindoria SV, Devkar R, Gupta I, Ranebennur V, Saggurti N, Ramesh S, et al. Development and pilot testing of HIV screening program integration within public/primary health centers providing antenatal care services in Maharashtra, India. BMC Res Notes. 2014;7(1):177.
115. Burke MJ, Shenton RC, Taylor MJ. The economics of screening infants at risk of hearing impairment: an international analysis. Int J Pediatr Otorhinolaryngol. 2012;76(2):212–8.
116. Singh SP, Hirve S, Huda MM, Banjara MR, Kumar N, Mondal D. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis. 2011;5(2):e960.
117. Pandav CS. Economic evaluation of iodine deficiency disorder control program in Sikkim: a cost effectiveness study. Indian J Public Heal. 2012;56(1):37–43.
118. Vassall A, Chandrashekar S, Pickles M, Beattie T, Shetty G, Bhattacharjee P, et al. Community mobilisation and empowerment interventions as part of HIV prevention for female sex workers in Southern India: A cost-effectiveness analysis. 2014;9(10):e110562.
119. Suraratdecha C, Jacobson J, Sivalenka S, Narahari D. A cost-effectiveness analysis of strategies for controlling Japanese encephalitis in Andhra Pradesh, India. J Pharm Financ Econ Policy. 2006;15(1):21–40.
120. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar. India. Trop Med Int Heal. 2009;14(8):918–25.
121. Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer. 2005;117(6):981–7.
122. Isaac MK, Kapur R. A cost-effectiveness analysis of three different methods of psychiatric case finding in the general population. Br J Psychiatry. 1980;137(6):540–6.
123. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBAand CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36(5 Suppl):MS1–9 (MS18–147).
124. Gavaza P, Rascati K, Oladapo AO, Khoza S. The State of Health Economic Research in South Africa: a systematic review. Pharmacoeconomics. 2012;30(10):925–40.
125. Teerawattananon Y, Russell S, Mugford M. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers? Pharmacoeconomics. 2007;25(6):467–79.
126. Tran BX, Nong VM, Maher RM, Nguyen PK, Luu HN. A systematic review of scope and quality of Health Economic Evaluation Studies in Vietnam. PLoS One. 2014;9(8):e103825. Available from: http://dx.plos.org/10.1371/journal.pone.0103825.
127. Hoque ME, Khan JAM, Hossain SSA, Gazi R, Rashid H, Koehlmoos TP, et al. A systematic review of economic evaluations of health and health-related interventions in Bangladesh. Cost Eff Resour Alloc. 2011;9:12. Available from:http://www.resource-allocation.com/content/9/1/12(BioMed Central Ltd).
128. Gavaza P, Rascati KL, Oladapo AO, Khoza S. The state of health economic evaluation research in Nigeria: a systematic review. Pharmacoeconomics. 2010;28(7):539–53.
129. Gavaza P, Rascati K, Brown C, Lawson K, Mann T. The state of health economic and pharmacoeconomic evaluation research in Zimbabwe: a review. Curr Ther Res Clin Exp. 2008;69(3):268–85.
130. Indian Health Economics and Policy Association (IHEPA) [Internet]. Available from: http://ihepa.in/. Cited 11 Mar 2015.
131. Health Economics Association of India (HEAI) [Internet]. Available from: http://www.heai.org.in/. Cited 11 Mar 2015.
132. Online Certificate Course in Basic Health Economics [Internet]. Available from: www.healtheconomics.pgisph.in. Cited 14 Mar 2015.
133. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2014–15: Punjab [Internet]. Available from: http://www.pbnrhm.org/docs/pip_admin_approval_14_15.pdf. Cited 25 Aug 2015.
134. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2014–15: Andhra Pradesh [Internet]. Available from: http://cfw.ap.nic.in/pdf/Final%20ROP%20Andhra%20Pradesh%202014-15.pdf. Cited 25 Aug 2015.
135. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM 2012–13: Haryana [Internet]. Available from: http://pipnrhm-mohfw.nic.in/PIP2012-13_files/ROP%202012/Haryana/Approval%20of%20State%20Programme%20Implementation%20Plan-Haryana,%202012-13.pdf. Cited 25 Aug 2015.
136. Ministry of Health and Family Welfare Government of India, National Rural Health Mission, Approval of State Programme Implementation Plan of NRHM: Himachal Pradesh, May 2012–13 [Internet]. Available from: http://pipnrhm-mohfw.nic.in/PIP2012-13_files/ROP%202012-13/Himachal%20Pradesh/Approval%20of%20State%20Programme%20Implementation%20Plan%20.pdf. Cited 25 Aug 2015.
137. National List of Essential Medicines of India 2011 [Internet. Available from: http://pharmaceuticals.gov.in/nlem.pdf. Cited 26 Aug 2015.
138. Essential Medicine List (2013–14) [Internet]. Available from: http://www.nrhmharyana.gov.in/files/essentialdruglist2013.pdf. Cited 26 Aug 2015.
139. List of Essential Drugs, 2013, Punjab [Internet]. Available from: http://punjabhealth.co.in/downloads.aspx?ID=nh5DUDN8odM=&&Header=+g1BOwyDm98sKB5ssQYvWAv9KLvK9BlY. Cited 26 Aug 2015.
140. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional and national levels of age-specific mortality and 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71
141. NICE signs MoU with the Department of Health Research, Ministry of Health and family welfare, Government of India [Internet]. Available from: http://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/niceinternational/projects/nicesignsmougovernmentindia.jsp. Cited 1 Jul 2015.
142. Verguet S, Laxminarayan R, Jamison DT. Universal Public Finance of Tuberculosis treatment in India: an extended cost-effectiveness analysis. Heal econ. 2015;24:318–32.
143. Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine [Internet]. 2013;31(42):4902–10 (Elsevier Ltd).
144. Megiddo I, Colson AR, Nandi A, Chatterjee S, Prinja S, Khera A, et al. Analysis of the Universal Immunization Programme and introduction of a rotavirus vaccine in India with IndiaSim. Vaccine [Internet]. 2014;32(S1):A151–61 (Elsevier Ltd).
145. Freemantle N, Mason J. Publication bias in clinical trials and economic analyses. Pharmacoeconomics. 1997;12(1):10–6.
146. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, Greenberg D. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332(7543):699–703.
147. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991;324(19):1362–5.
148. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: an ISPOR Task Force Report. Value Health. 2013;16:231–50.